NCT06752473View on ClinicalTrials.gov

KSD-101 Therapy for Standard Treatment Failed EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

February 28, 2027

Conditions
Nasopharyngeal Carcinoma (NPC)EBV
Interventions
BIOLOGICAL

KSD-101

Patients will receive approximately 5x10\^6 DC vaccine via subcutaneous injections bi-weekly,total 3-5 times.

All Listed Sponsors
lead

Kousai Bio Co., Ltd.

OTHER